Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1B | P35368 | 1/20 | 0.45 |
| ▸ | GFER | P55789 | 1/20 | 0.44 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.43 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | TP53 | P04637 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6763593 | 0.95 | ADRA1B (0.49) | ADRA1BGFERAPOBEC3AAPOBEC3GGAA | |
| SCHEMBL28834312 | 0.80 | KEAP1 (0.53) | GFERAPOBEC3AAPOBEC3GGAAKDM4E | |
| SCHEMBL12569511 | 0.79 | DDB1 (0.54) | ADRA1BPOLBALDH1A1HPGDMAPT | |
| SCHEMBL15108903 | 0.79 | MEN1 (0.61) | GFERAPOBEC3AAPOBEC3GGAAALDH1A1 | |
| SCHEMBL1439000 | 0.79 | GFER (0.44) | GFERAPOBEC3AAPOBEC3GALDH1A1HPGD | |
| SCHEMBL31056512 | 0.78 | APOBEC3A (0.52) | GFERAPOBEC3AAPOBEC3GGAAPOLB | |
| SCHEMBL20103130 | 0.77 | ADRA1A (0.48) | ADRA1BAPOBEC3AAPOBEC3GPOLBALDH1A1 | |
| SCHEMBL11066854 | 0.77 | SMN1; SMN2 (0.41) | ADRA1BGAAKDM4EPOLBALDH1A1 | |
| SCHEMBL6568198 | 0.77 | NPC1 (0.59) | GFERAPOBEC3AAPOBEC3GKDM4EPOLB | |
| SCHEMBL610033 | 0.76 | DDAH1 (0.49) | KDM4EPOLBALDH1A1HPGDCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1858546-A4 | MODIFIED TRANSFERRIN FUSION PROTEINS | BIOREXIS PHARMACEUTICAL CORP (US) | 2009-03-04 | — | — | EP | disclosed |
| EP-1814599-A4 | COMBINATION THERAPY USING TRANSFERRIN FUSION PROTEINS COMPRISING GLP-1 | BIOREXIS PHARMACEUTICAL CORP (US) | 2008-12-17 | — | — | EP | disclosed |
| EP-1858546-A2 | MODIFIED TRANSFERRIN FUSION PROTEINS | Biorexis Pharmaceutical Corporation (US) | 2007-11-28 | — | — | EP | disclosed |
| CN-101035568-A | Combination therapy using transferrin fusion proteins comprising GLP-1 | BIOREXIS PHARMACEUTICAL CORP (US) | 2007-09-12 | — | — | CN | disclosed |
| EP-1814599-A2 | COMBINATION THERAPY USING TRANSFERRIN FUSION PROTEINS COMPRISING GLP-1 | Biorexis Pharmaceutical Corporation (US) | 2007-08-08 | — | — | EP | disclosed |
| US-20070060512-A1 | Dipeptidyl-peptidase protected protein | BIOREXIS PHARMACEUTICAL CORPORATION | 2007-03-15 | — | — | US | disclosed |
| EP-1626981-A4 | DIPEPTIDYL-PEPTIDASE PROTECTED PROTEINS | BIOREXIS PHARMACEUTICAL CORP (US) | 2006-11-22 | — | — | EP | disclosed |
| WO-2006096515-A2 | MODIFIED TRANSFERRIN FUSION PROTEINS | BIOREXIS PHARMACEUTICAL CORPORATION (US) | 2006-09-14 | — | — | WO | disclosed |
| US-20060205037-A1 | Modified transferrin fusion proteins | BIOREXIS PHARMACEUTICAL CORPORATION | 2006-09-14 | — | — | US | disclosed |
| WO-2006049983-A2 | PEPTIDE YY MODIFIED TRANSFERRIN FUSION PROTEINS | BIOREXIS PHARMACEUTICAL CORPORATION (US) | 2006-05-11 | — | — | WO | disclosed |
| WO-2006017688-A2 | COMBINATION THERAPY USING TRANSFERRIN FUSION PROTEINS COMPRISING GLP-1 | BIOREXIS PHARMACEUTICAL CORPORATION (US) | 2006-02-16 | — | — | WO | disclosed |
| WO-2004078777-A2 | DIPEPTIDYL-PEPTIDASE PROTECTED PROTEINS | BIOREXIS PHARMACEUTICAL CORPORATION (US) | 2004-09-16 | — | — | WO | disclosed |
| US-20030220241-A1 | Method of treating cancer | DEFEO-JONES DEBORAH (US) | 2003-11-27 | — | — | US | disclosed |
| US-20020037888-A1 | 4-imidazol-1-ylmethyl-2-(2-(2-oxo-piperidin-1-yl)-phenoxy) -benzonitrile for example; farnesyl-protein transferase inhibitors; treating cancer, benign proliferative disorder, hepatitis virus, restenosis, and polycystic kidney disease | MERCK & CO., INC. | 2002-03-28 | — | — | US | disclosed |
| US-6284755-B1 | Inhibitors of prenyl-protein transferase | MERCK & CO., INC. | 2001-09-04 | — | — | US | disclosed |
| WO-2000059930-A1 | A METHOD OF TREATING CANCER | MERCK & CO., INC. (US) | 2000-10-12 | — | — | WO | disclosed |
| US-6100300-A | A THERAPEUTIC TREATMENT OF DEFICIENT BLOOD SUPPLY IN EXERCISING MUSCLE | BRISTOL-MYERS SQUIBB COMPANY (US) | 2000-08-08 | — | — | US | disclosed |
| WO-2000034437-A2 | INHIBITORS OF PRENYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 2000-06-15 | — | — | WO | disclosed |
| US-4024267-A | THERAPY OF HYPERLIPIDEMIA | HOECHST AKTIENGESELLSCHAFT (DT) | 1977-05-17 | — | — | US | disclosed |
| US-4024267-A | THERAPY OF HYPERLIPIDEMIA | HOECHST AKTIENGESELLSCHAFT (DT) | 1977-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030220241-A1 | Method of treating cancer | ACP3, PSAT1, LCAT | ADRA1B 4462/4885GFER 3789/4885APOBEC3A 3364/4885 |
| US-20020037888-A1 | 4-imidazol-1-ylmethyl-2-(2-(2-oxo-piperidin-1-yl)-phenoxy) -benzonitrile for example; farnesyl-protein transferase inhibitors; treating cancer, benign proliferative disorder, hepatitis virus, restenosis, and polycystic kidney disease | FNTA, PKD1, FNTB | ADRA1B 4484/4885GFER 2552/4885APOBEC3A 3364/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.